<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="tbl1" position="float">
 <label>Table 1</label>
 <caption>
  <title>Clinical Classification of COVID-19 Patients and the Corresponding Therapeutic Regimen According to the Seventh Edition of the Guidelines for the Diagnosis and Treatment of COVID-19 Issued by the NHC of China
   <sup>
    <xref ref-type="bibr" rid="ref14">14</xref>
   </sup>,
   <xref rid="t1fn1" ref-type="table-fn">a</xref>
  </title>
 </caption>
 <table frame="hsides" rules="groups" border="0">
  <colgroup>
   <col align="left"/>
   <col align="left"/>
   <col align="left"/>
  </colgroup>
  <thead>
   <tr>
    <th style="border:none;" align="center">clinical classification</th>
    <th style="border:none;" align="center">criteria for classification</th>
    <th style="border:none;" align="center">therapeutic regimen</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td style="border:none;" align="center">Mild</td>
    <td style="border:none;" align="left">Nonspecific clinical symptoms and no manifestation of pneumonia based on medical imaging.</td>
    <td style="border:none;" align="left">
     <bold>General treatment:</bold>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="center">Moderate</td>
    <td style="border:none;" align="left">Fever and respiratory tract symptoms, and manifestation of pneumonia based on medical imaging.</td>
    <td style="border:none;" align="left">(1) Stay in bed to rest, strengthen supportive treatment, keep a balanced diet and maintain the balance of water and electrolytes.</td>
   </tr>
   <tr>
    <td rowspan="6" style="border:none;" align="center" valign="middle">Severe</td>
    <td style="border:none;" align="left">At least one of the following symptoms in adults:</td>
    <td style="border:none;" align="left">(2) Effective oxygen therapies, including nasal catheter oxygen inhalation, oxygen inhalation with a mask or high-flow nasal cannula with a hydrogen and oxygen mixture (H
     <sub>2</sub>/O
     <sub>2</sub>) of 66.6%/33.3%, if possible.
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">(1) Respiratory distress, respiration rate (RR) &gt; 30/min;</td>
    <td style="border:none;" align="left">(3) Antiviral therapies: IFN-α nebulization (5 × 10
     <sup>6</sup> units or equivalent per time, add 2 mL of sterile water, aerosol inhalation, BID); lopinavir/ritonavir (200 mg/50 mg per capsule, 2 capsules each time, BID); ribavirin (500 mg by venoclysis per time, BID, combination treatment with IFN-α or lopinavir/ritonavir are recommended); CQ phosphate (500 mg per time, BID), Arbidol (200 mg per time, TID). The above dosages are suitable only for adults, and the course of treatment with above antivirals should be ≤10 days. Monitor side effects such as diarrhea, nausea, vomiting, and liver damage related to lopinavir/ritonavir as well as harmful interactions with other drugs. Simultaneous use of three or more types of antiviral drugs is not recommended, and relevant drug treatments should be stopped if unbearable side effects occur.
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">(2) Pulse oxygen saturation (SpO
     <sub>2</sub>) of ≤93% at resting state;
    </td>
    <td style="border:none;" align="left">(4) Traditional Chinese medicine (TCM) treatments, shown in 
     <xref rid="tbl2" ref-type="other">Table 
      <xref rid="tbl2" ref-type="other">2</xref>
     </xref>.
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">(3) Arterial partial pressure of oxygen (PaO
     <sub>2</sub>)/oxygen concentration (FiO
     <sub>2</sub>) of ≤300 mmHg.
    </td>
    <td style="border:none;" align="left">
     <bold>Treatment of severe and critical cases:</bold>
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">For high altitude regions (above 1000 m), PaO
     <sub>2</sub>/FiO
     <sub>2</sub> should be adjusted based on equation of PaO
     <sub>2</sub>/FiO
     <sub>2</sub> × (atmospheric pressure (mmHg)/760).
    </td>
    <td style="border:none;" align="left">(1) Respiratory support: oxygen inhalation, noninvasive ventilation, invasive ventilation; salvage therapies (lung recruitment), and extracorporeal membrane oxygenation (ECMO).</td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Patients with &gt;50% lesions progression within 24–48 h in pulmonary imaging should be treated as severe cases of COVID-19.</td>
    <td style="border:none;" align="left">(2) Circulatory support: on the basis of adequate fluid resuscitation, improved microcirculation, and</td>
   </tr>
   <tr>
    <td rowspan="6" style="border:none;" align="center" valign="middle">Critical</td>
    <td style="border:none;" align="left">Meeting any of the following:</td>
    <td style="border:none;" align="left">(3) Use of vasoactive drugs.</td>
   </tr>
   <tr>
    <td style="border:none;" align="left">(1) Respiratory failure occurs and mechanical ventilation is required;</td>
    <td style="border:none;" align="left">(4) Renal replacement therapy for patients with renal failure.</td>
   </tr>
   <tr>
    <td style="border:none;" align="left">(2) Shock;</td>
    <td style="border:none;" align="left">(5) Convalescent-phase plasma therapy.</td>
   </tr>
   <tr>
    <td style="border:none;" align="left">(3) Complicated with other organ failure that requires monitoring and treatment in an intensive care unit (ICU).</td>
    <td style="border:none;" align="left">(6) Blood dialysis.</td>
   </tr>
   <tr>
    <td style="border:none;" align="left"> </td>
    <td style="border:none;" align="left">(7) Immunotherapy: trastuzumab for patients with a high IL-6 level.</td>
   </tr>
   <tr>
    <td style="border:none;" align="left"> </td>
    <td style="border:none;" align="left">(8) Other therapies, including low dosage of methylprednisolone (≤1–2 mg kg
     <sup>–1</sup> day
     <sup>–1</sup>) and intestinal microecological regulators.
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn id="t1fn1">
   <label>a</label>
   <p>BID, twice a day; TID, three times a day.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
